Aspirin in Patients With Myocardial Infarction and Thrombocytopenia

• Status: Terminated
• Trial end date: 2008-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary Objective:

To determine the risk of bleeding from ASA therapy in thrombocytopenic patients who develop Acute Coronary Syndrome (ACS), and assess its effect on the overall morbidity and mortality in these patients as well as platelet functions.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Treatments: Aspirin

Criteria

Inclusion Criteria:

1. Presenting for Cardiology consult at M.D. Anderson Cancer Center.

2. Platelet count between 100,000 and 20,000.

3. Acute Coronary Syndrome diagnosed with their first 12 lead EKG.

4. Patients that continue to show evidence of MI by cardiac enzymes with CPK levels > 2 normal limits, CK-MB levels 10% above normal limits, and Troponin I levels > 1.4ug/L will be considered positive for MI.

5. Ability to give consent.

Exclusion Criteria:

1. Contraindications to aspirin including severe intolerance or true allergy, active bleeding, hemophilia, active retinal bleeding, severe untreated hypertension, active peptic ulcer, or other significant source of gastrointestinal or genitourinary bleeding, brain metastasis, and altered mental status.

2. Unwillingness or inability to give consent.

3. Progressive heart failure, unstable angina not responding to medical therapy for 24 hours, or ventricular tachycardia, necessitating thrombolysis, and angioplasty.

4. Patients that rule out for MI by cardiac enzymes panel after the first 24 hours.

5. Patients that rule in for MI and have Platelet count > 100,000.

6. Patients with platelet count < 20,000.